[1] 陈规划,张琪. 肝癌生物治疗的现状与展望. 外科理论与实践,2012, 17 : 434-436.
[2] Olioso P,Giancola R,Di Riti M,et al.Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours:a pilot clinical trial.Hematol Oncol,2009,27:130-139.
[3] Wu c,Jiang J,shi L,et al.Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer.Anticancer Res,2008,28:3997-4002.
[4] Geller MA, Miller JS.Use of allogeneic NK cells for cancer immunotherapy.Immunotherapy,2011:1445-1459.
[5] Imhof M,Karas I,Gomez I,et al. Interaction of tumor cells with the immune system:implications for dendritic cell therapy and cancer progression.Drug Discov Today,2013,18:35-42.
[6] Tada F, Abe M, Hirooka M, et al. Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Int J Oncol, 2012, 41: 1601-1609.
[7] 王广伟,顾元龙,刘敏丰. 负载自身肿瘤裂解物的树突状细胞联合杀伤细胞对肝癌患者术后免疫功能的影响.中华普通外科杂志,2012,27: 337-338.
[8] Cui J, Wang N, Zhao H, et al. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int J Cancer, 2014, 134: 342-351. |
